FY2024 EPS Estimates for Liquidia Increased by Analyst

Liquidia Co. (NASDAQ:LQDA - Free Report) - Stock analysts at Lifesci Capital raised their FY2024 earnings per share estimates for Liquidia in a report released on Wednesday, November 13th. Lifesci Capital analyst C. Jubinville now forecasts that the company will post earnings per share of ($1.48) for the year, up from their previous forecast of ($1.57). Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Liquidia's current full-year earnings is ($1.55) per share. Lifesci Capital also issued estimates for Liquidia's Q4 2024 earnings at ($0.36) EPS.

Other analysts have also issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday. Bank of America reduced their price objective on Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Tuesday, August 20th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday. BTIG Research cut their price target on Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Monday, August 19th. Finally, Raymond James raised Liquidia from an "outperform" rating to a "strong-buy" rating in a research note on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Liquidia currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Liquidia Price Performance

NASDAQ:LQDA traded down $0.06 during trading hours on Monday, hitting $9.78. The company's stock had a trading volume of 16,534 shares, compared to its average volume of 976,989. The stock has a fifty day simple moving average of $10.52 and a 200-day simple moving average of $11.48. The company has a market capitalization of $827.78 million, a P/E ratio of -6.04 and a beta of 0.21. Liquidia has a twelve month low of $6.33 and a twelve month high of $16.99.

Insider Activity at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the transaction, the chief financial officer now directly owns 311,076 shares of the company's stock, valued at approximately $3,456,054.36. The trade was a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caligan Partners Lp purchased 150,000 shares of the company's stock in a transaction on Friday, August 30th. The stock was acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the purchase, the director now owns 6,994,997 shares of the company's stock, valued at approximately $66,522,421.47. This trade represents a 2.19 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 21,551 shares of company stock worth $236,021 over the last ninety days. Insiders own 30.10% of the company's stock.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently modified their holdings of the company. Patient Square Capital LP bought a new position in Liquidia in the 1st quarter valued at $105,942,000. Vanguard Group Inc. lifted its holdings in Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock worth $42,587,000 after purchasing an additional 43,352 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Liquidia during the 1st quarter worth about $30,311,000. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after acquiring an additional 927,546 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after acquiring an additional 230,820 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).